Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) EBT (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed EBT for 4 consecutive years, with -$23.3 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 60.68% to -$23.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$109.3 million, a 44.69% increase, with the full-year FY2025 number at -$109.3 million, down 23.71% from a year prior.
  • EBT was -$23.3 million for Q4 2025 at Day One Biopharmaceuticals, down from -$19.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $35.0 million in Q3 2024 to a low of -$110.8 million in Q2 2024.
  • A 4-year average of -$39.9 million and a median of -$38.9 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 175.75% in 2024, then tumbled 156.33% in 2025.
  • Day One Biopharmaceuticals' EBT stood at -$40.1 million in 2022, then tumbled by 35.95% to -$54.5 million in 2023, then dropped by 8.78% to -$59.3 million in 2024, then soared by 60.68% to -$23.3 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's EBT are -$23.3 million (Q4 2025), -$19.7 million (Q3 2025), and -$30.3 million (Q2 2025).